Novel GLP-1 (Glucagon-like peptide-1) analogues and insulin in the treatment for alzheimers disease and other neurodegenerative diseases
No complaints
For example, semaglutide has more extensive cardiovascular outcome data (from the SELECT trial), which may matter for patients with significant heart disease risk
Mounting evidence from multi-omics studies implicates microbial imbalance in the pathogenesis of diverse disease states, spanning metabolic syndrome, autoimmune disorders, and neuropsychiatric conditions (Ding et al., 2024)
With semaglutide, total alcohol intake decreased by 1,550 g/30 days, compared with an approximate reduction of 1,026 g/30 days in the placebo group (estimated between-group difference of ~468 g/30 days), and the number of drinks per day decreased by 3.5 units
This DIY beauty recipe is perfect for keeping your skin hydrated and glowing